Vinita Schroeder, MD
Allergy & Immunology · Dallas, TXNPI 1750498713
Payments from drug & device makers
Across 122 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$588
- Sanofi$393
- Kaleo, Inc.$178
- Takeda Pharmaceuticals U.S.A., Inc.$154
- Pfizer$129
- GSK$121
- plus $728 from 16 others
What the payments were for
- Food & beverage$2,291100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 31 | $588 |
| Sanofi | 19 | $393 |
| Kaleo, Inc. | 11 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $154 |
| Pfizer | 7 | $129 |
| GSK | 8 | $121 |
| AstraZeneca | 7 | $113 |
| Optinose US, Inc. | 4 | $77 |
| Grifols USA, LLC | 4 | $74 |
| Novartis | 3 | $71 |
| CSL Behring | 3 | $62 |
| Hospira, Inc. | 3 | $56 |
| Galderma Laboratories, L.p. | 2 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Genentech USA, Inc. | 2 | $41 |
| Octapharma USA, Inc. | 1 | $32 |
| Organon | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $14 |
How this compares
$2,291 in reported general payments places this provider in the 30th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Dallas
- Barbara BaxterDallas$2.5M
- Richard WassermanDallas$1.9M
- Elliot GinchanskyDallas$477K
- Matthew FeldmanDallas$410K
- Lara GrossDallas$171K
- Anil NandaDallas$86K
- Sonak DaulatDallas$72K
- Joseph WestDallas$39K
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.